SAB Biotherapeutics, Inc. (SABS)

Market Cap	276.57M +96.2%
Revenue (ttm)	n/a
Net Income	-66.50M
EPS	-1.49
Shares Out	90.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	676,897
Open	3.070
Previous Close	3.100
Day's Range	2.960 - 3.135
52-Week Range	2.440 - 5.150
Beta	0.75
Analysts	Strong Buy
Price Target	11.64 (+279.15%)
Earnings Date	Nov 5, 2026

About SABS

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 86
• Stock Exchange: Nasdaq
• Ticker Symbol: SABS
• Website: https://www.sab.bio

Analyst Summary

According to 11 analysts, the average rating for SABS stock is "Strong Buy." The 12-month stock price target is $11.64, which is an increase of 279.15% from the latest price.

Price Target

$11.64

(279.15% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 10, 2026

Data Sources Report a data error